0001209191-22-020076.txt : 20220318
0001209191-22-020076.hdr.sgml : 20220318
20220318173239
ACCESSION NUMBER: 0001209191-22-020076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220317
FILED AS OF DATE: 20220318
DATE AS OF CHANGE: 20220318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROYSTON IVOR
CENTRAL INDEX KEY: 0001026765
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51531
FILM NUMBER: 22753591
MAIL ADDRESS:
STREET 1: 4401 WILSHIRE BLVD.
STREET 2: SUITE 200
CITY: LOS ANGELES
STATE: CA
ZIP: 90010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viracta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001061027
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943295878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
BUSINESS PHONE: 858-400-8470
MAIL ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
FORMER COMPANY:
FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980709
FORMER COMPANY:
FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-17
0
0001061027
Viracta Therapeutics, Inc.
VIRX
0001026765
ROYSTON IVOR
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF
CA
92007
1
1
0
0
CEO & President
Stock Option (Right to Buy)
3.04
2022-03-17
4
A
0
412500
0.00
A
2032-03-17
Common Stock
412500
412500
D
One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.
/s/ Daniel Chevallard, as Attorney-in-Fact
2022-03-18
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Viracta Therapeutics, Inc.
(the "Company"), hereby constitutes and appoints Daniel Chevallard, Stewart
Brown, Shelly Vandertie, Ben Capps, and Brandon Shaw the undersigned's true and
lawful attorneys-in-fact to:
1. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorneys-in-fact shall in their discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigned's ownership,
acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorneys-in-fact shall deem
appropriate.
The undersigned hereby ratifies and confirms all that said attorneys in-fact and
agent shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 18th day of March, 2022.
Signature: /s/ Ivor Royston
Print Name: Ivor Royston